Welcome to our dedicated page for The Cooper Companies news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on The Cooper Companies stock.
The Cooper Companies, Inc. reports developments for a global medical device business organized around CooperVision and CooperSurgical. CooperVision news centers on soft contact lenses, specialty lens designs, myopia management products such as MiSight® 1 day, MyDay® contact lenses, practitioner support, and sustainability initiatives tied to lens materials, packaging, manufacturing, and plastic footprint programs.
CooperCompanies news also covers quarterly financial results, conference participation, board appointments, and governance matters. CooperSurgical provides fertility and women’s healthcare products, while companywide updates describe operating performance, capital priorities, and corporate developments across its medical device portfolio.
CooperCompanies (COO) opened CooperVision’s global innovation hub, The Vision Centre, and outlined six contact lens advancements on September 23, 2026. The Southampton, England, facility brings together research and development, clinical expertise, pilot manufacturing and commercial capabilities.
The planned advancements include a family of daily lenses for myopia control; premium and entry-level daily silicone hydrogel lenses; a monthly lens using a new silicone hydrogel material; and two daily toric lenses, including a multifocal design. Toric lenses are designed for astigmatism. CooperVision expects to launch the advancements over the next several years.
CooperVision (COO) has opened The Vision Centre, a new global innovation hub in Southampton, England, and outlined six accelerated contact lens pipeline advancements.
The company plans to introduce a full 1‑day myopia control lens family, multiple new 1‑day silicone hydrogel (SiHy) technologies, a next‑generation SiHy monthly lens, a differentiated entry 1‑day SiHy product, an advanced 1‑day SiHy toric multifocal lens, and a new toric 1‑day experience for astigmatic patients. The 9,940‑square‑meter facility will house about 350 employees and is designed to link R&D, clinical work, pilot manufacturing, and commercial teams to speed development and commercialization of new eye care solutions.
Summary not available.
CooperCompanies (COO) reported fiscal third quarter 2026 revenue of $1.066 billion, up 1% year-over-year with 1% organic growth.
GAAP diluted EPS rose to $2.24 from $0.49, primarily reflecting a $307.2 million discrete tax benefit from a favorable U.K. tax examination, while non-GAAP diluted EPS increased 4% to $1.15. Non-GAAP operating margin improved 30 basis points to 26% and free cash flow climbed 66% to $273.0 million. CooperVision revenue was flat at $717.0 million, with strength in toric and multifocal lenses offset by declines in sphere and Asia Pacific. CooperSurgical revenue grew 2% to $349.2 million, with fertility organic growth of 5%.
The company repurchased $339.1 million of stock and expanded its authorization to $3 billion. Fiscal 2026 guidance calls for 2%–3% organic revenue growth and non-GAAP EPS of $4.51–$4.55, and management reaffirmed a long-term free cash flow objective exceeding $2.2 billion for 2026–2028.
CooperCompanies (COO) completed its strategic review and the Board unanimously decided to retain CooperSurgical rather than pursue a sale at this time.
The Board expanded the share repurchase authorization from $2 billion to $3 billion, after the company repurchased $445 million of shares in the current fiscal year, citing confidence in its intrinsic value. During the review, two new independent directors with healthcare, operational and capital allocation experience joined the Board. The company outlined operational initiatives, including expanded CooperVision sales and marketing, cost and efficiency programs, revised inventory and logistics, and accelerated innovation supported by the September 23, 2026 opening of The Vision Centre R&D hub.
The Canadian Association of Optometrists (CAO) launched a digital awareness campaign, “Myopia Can Hide in Plain Sight,” to promote regular comprehensive eye exams for children and address rising myopia. The campaign runs throughout August on Facebook, Instagram and YouTube in English and French, supported by Alcon and CooperVision (Nasdaq: COO).
CAO recommends eye exams starting at 6–9 months, again between ages 2–5, and annually to age 19. According to CAO, early detection of myopia is vital, as higher levels increase risks of retinal detachment, cataracts, glaucoma and myopic maculopathy, with global prevalence projected to reach 50% by 2050.
CooperCompanies (Nasdaq: COO) announced it will release its third quarter 2026 financial results on Wednesday, September 9, 2026, at 4:15 PM ET. The company will then host a conference call at 5:00 PM ET to discuss the results and current corporate developments, with an audio webcast and replay available at its investor relations website.
CooperSurgical (NYSE:COO) announced support for Saving Mothers, a nonprofit focused on reducing maternal morbidity and mortality worldwide. The collaboration aims to advance women’s health by improving access to care, education, and life‑saving interventions.
The partnership aligns with Fibroid Awareness Month and highlights conditions such as fibroids and endometriosis, emphasizing earlier diagnosis, better treatment options, and global health education through initiatives like the YouTube talk show Health Starts with Her and CooperSurgical’s uterine health solutions.
CooperCompanies (Nasdaq: COO) released its 2025 Corporate Sustainability Report, highlighting expanded metrics and progress on environmental and social priorities. A major milestone is the first-time disclosure of Scope 3 greenhouse gas emissions, increasing transparency.
The report aligns with SASB Standards and, for the first time, TCFD recommendations, and details initiatives across CooperVision and CooperSurgical.
CooperCompanies (Nasdaq: COO) reported fiscal Q2 2026 revenue of $1.082 billion, up 8% year over year and 5% organically. GAAP diluted EPS was $(0.40), reflecting a litigation-related charge tied to a December 2023 fertility media recall, while non-GAAP diluted EPS rose to $1.21, up 26%.
Non-GAAP operating margin improved to 27%. CooperVision revenue was $723.5 million and CooperSurgical revenue $358.0 million, both up 8%. Free cash flow reached $96.4 million. Fiscal 2026 guidance calls for revenue of $4.285–$4.321 billion and non-GAAP EPS of $4.58–$4.66.